NAPLEX Quiz: Recognition And Management

What this quiz covers

This quiz focuses on Recognition And Management, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Serum potassium and serum creatinine within 1–2 weeks of initiation (correct answer)
2. International normalized ratio (INR) within 3–5 days of initiation
3. Creatine kinase weekly for 1 month
4. Thyroid-stimulating hormone (TSH) in 6–8 weeks

Explanation: This question tests monitoring priorities when initiating ACE inhibitors in patients with risk factors for adverse effects. The patient has two significant risk factors for ACE inhibitor-induced hyperkalemia and acute kidney injury: concurrent NSAIDs (ibuprofen) and diuretic therapy (hydrochlorothiazide). The triple combination of ACE inhibitor + NSAID + diuretic significantly increases risk of renal dysfunction. Monitoring potassium and creatinine within 1-2 weeks is essential to detect these complications early. INR monitoring (choice B) is not relevant as lisinopril doesn't affect coagulation. Creatine kinase (choice C) monitors for statin myopathy, not ACE inhibitor effects. TSH monitoring (choice D) is not indicated for ACE inhibitors. When starting ACE inhibitors in patients taking NSAIDs or diuretics, check renal function and potassium within 1-2 weeks, and counsel patients to minimize NSAID use when possible.

Question 2

1. Continue simvastatin 40 mg nightly and add gemfibrozil 600 mg twice daily for additional LDL lowering
2. Increase simvastatin to 80 mg nightly for improved efficacy with amlodipine
3. Switch simvastatin to atorvastatin 40 mg nightly to avoid the simvastatin-amlodipine interaction (correct answer)
4. Reduce amlodipine to 2.5 mg once daily and continue simvastatin 40 mg nightly

Explanation: This question tests recognition of the simvastatin-amlodipine drug interaction and appropriate management. Amlodipine is a moderate CYP3A4 inhibitor that increases simvastatin exposure, with FDA guidance limiting simvastatin to 20 mg daily when used with amlodipine due to increased myopathy risk. The patient's new muscle aches suggest possible statin myopathy from this interaction. Switching to atorvastatin 40 mg avoids the dose limitation while maintaining potent statin therapy for her coronary artery disease. Adding gemfibrozil (choice A) would dangerously increase myopathy risk. Increasing simvastatin to 80 mg (choice B) violates FDA recommendations and worsens toxicity risk. Reducing amlodipine (choice D) may compromise blood pressure control. When patients on amlodipine require statin doses above simvastatin 20 mg daily, switch to atorvastatin or rosuvastatin, which have no dose restrictions with amlodipine.

Question 3

1. Continue warfarin 5 mg once daily and recheck INR in 4 weeks because amiodarone does not affect INR
2. Hold warfarin for 1 dose and decrease the weekly warfarin dose (for example, by ~30–50%) with close INR follow-up (correct answer)
3. Increase warfarin to 7.5 mg once daily because the INR goal in atrial fibrillation is 3.0–4.0
4. Discontinue amiodarone immediately and continue warfarin 5 mg once daily without INR recheck

Explanation: This question tests management of the warfarin-amiodarone drug interaction. Amiodarone is a potent CYP2C9 inhibitor that significantly increases warfarin levels, typically causing INR elevation within 1-2 weeks of initiation. The patient's INR of 4.6 (goal 2-3) after 10 days of amiodarone confirms this interaction. Holding one warfarin dose and reducing the weekly dose by 30-50% with close monitoring is the appropriate management strategy. Continuing without adjustment (choice A) ignores the documented interaction and elevated INR. The INR goal remains 2-3 for atrial fibrillation, not 3-4 (choice C). Discontinuing amiodarone (choice D) is inappropriate as it was likely started for rhythm control. When initiating amiodarone in patients on warfarin, empirically reduce warfarin dose by 30-50% and monitor INR closely, as the interaction can persist for weeks after amiodarone discontinuation due to its long half-life.

Question 4

1. Continue omeprazole and clopidogrel together because there is no clinically meaningful interaction
2. Switch omeprazole to pantoprazole 40 mg once daily to reduce potential reduction in clopidogrel activation (correct answer)
3. Discontinue atorvastatin 80 mg nightly because high-intensity statins are contraindicated after transient ischemic attack
4. Add warfarin 5 mg once daily for additional stroke prevention and stop aspirin

Explanation: This question tests management of drug interactions affecting antiplatelet therapy efficacy. Omeprazole inhibits CYP2C19, the enzyme responsible for converting clopidogrel to its active metabolite, potentially reducing its antiplatelet effect and increasing cardiovascular risk. This is particularly concerning in a patient recently hospitalized for TIA who needs optimal secondary stroke prevention. Switching to pantoprazole, which has minimal CYP2C19 inhibition, maintains gastroprotection while preserving clopidogrel efficacy. Continuing the combination (choice A) ignores FDA warnings about this interaction. High-intensity statins are indicated, not contraindicated, after TIA (choice C). Adding warfarin (choice D) isn't appropriate for TIA and would increase bleeding risk with dual therapy. When patients require both clopidogrel and PPI therapy, use pantoprazole or lansoprazole instead of omeprazole or esomeprazole to avoid compromising antiplatelet efficacy.

Question 5

1. Continue both metoprolol and diltiazem at current doses and add hydrochlorothiazide 25 mg once daily for blood pressure control
2. Discontinue diltiazem and continue metoprolol succinate 100 mg once daily (correct answer)
3. Switch metoprolol succinate to carvedilol 25 mg twice daily and continue diltiazem extended-release 240 mg once daily
4. Reduce metoprolol succinate to 50 mg once daily and continue diltiazem extended-release 240 mg once daily

Explanation: This question tests recognition of symptomatic bradycardia caused by concurrent use of two negative chronotropic agents. The patient's heart rate of 44 bpm with hypotension and symptoms of dizziness/near-syncope indicates excessive AV nodal blockade from the combination of metoprolol (beta-blocker) and diltiazem (non-dihydropyridine calcium channel blocker). Discontinuing diltiazem and continuing metoprolol is the best choice because it eliminates the drug interaction while maintaining beta-blockade for the patient's stable angina. Continuing both agents with a diuretic (choice A) would worsen hypotension without addressing the bradycardia. Switching to carvedilol while continuing diltiazem (choice C) maintains the problematic combination. Reducing metoprolol while continuing diltiazem (choice D) may not adequately resolve the bradycardia. When patients develop symptomatic bradycardia from concurrent negative chronotropes, discontinue one agent rather than reducing doses of both.

Question 6

1. Continue metformin 1000 mg twice daily and add pioglitazone 45 mg once daily
2. Reduce metformin to 500 mg twice daily and reassess renal function in 3 months
3. Discontinue metformin due to reduced renal function and recommend adding basal insulin (for example, insulin glargine) with titration (correct answer)
4. Switch glipizide to glyburide 10 mg twice daily for improved glycemic control

Explanation: This question tests recognition of metformin contraindications in chronic kidney disease. The patient's estimated creatinine clearance of 38 mL/min falls below the threshold for safe metformin use (eGFR <45 mL/min/1.73m²), requiring discontinuation to prevent lactic acidosis risk. With an A1c of 9.4% despite dual oral therapy, adding basal insulin is the most appropriate next step for this patient with reduced renal function. Adding pioglitazone (choice A) doesn't address the metformin contraindication. Simply reducing the metformin dose (choice B) is insufficient when eGFR is <45 mL/min/1.73m². Switching sulfonylureas (choice D) doesn't improve glycemic control or address the metformin issue. When patients with diabetes develop renal impairment with eGFR <45 mL/min/1.73m², metformin must be discontinued, and insulin therapy often becomes necessary for adequate glycemic control.

Question 7

1. Stop trimethoprim-sulfamethoxazole and refer for urgent evaluation due to possible angioedema; update allergy to sulfonamide antibiotic (correct answer)
2. Continue trimethoprim-sulfamethoxazole and add diphenhydramine 25 mg every 6 hours as needed until symptoms resolve
3. Switch to cephalexin 250 mg once daily for 3 days without contacting the prescriber
4. Stop lisinopril and continue trimethoprim-sulfamethoxazole because the reaction is more consistent with ACE inhibitor cough

Explanation: This question tests recognition and management of a severe hypersensitivity reaction to trimethoprim-sulfamethoxazole. The patient presents with diffuse hives and lip swelling (angioedema) within 2 days of starting the antibiotic, which is characteristic of a Type I hypersensitivity reaction. Immediate discontinuation and urgent referral is the best choice because angioedema can progress to life-threatening airway obstruction. Adding diphenhydramine while continuing the offending drug (choice B) is dangerous and inappropriate. Switching antibiotics without prescriber contact (choice C) exceeds pharmacist scope and doesn't address the acute reaction. The timing and presentation are inconsistent with ACE inhibitor cough (choice D), which is a dry cough without urticaria or angioedema. When patients develop angioedema or severe urticaria from any medication, immediate discontinuation and urgent medical evaluation are mandatory, with documentation of the allergy to prevent future exposure.

Question 8

1. Decrease insulin glargine to 10 units nightly and continue glipizide 10 mg twice daily
2. Discontinue glipizide and continue insulin glargine and metformin at current doses (correct answer)
3. Switch glipizide to glyburide 10 mg by mouth twice daily to reduce hypoglycemia
4. Increase metformin to 1500 mg by mouth twice daily and continue glipizide 10 mg twice daily

Explanation: This question tests the recognition and management of hypoglycemia in type 2 diabetes patients on multiple antidiabetic agents. The key patient-specific factor is the recent glipizide dose increase leading to frequent hypoglycemia symptoms with an A1c of 6.4%, indicating overtreatment. Discontinuing glipizide while continuing insulin glargine and metformin is the best choice because sulfonylureas like glipizide carry a high risk of hypoglycemia, especially in older adults, and removal reduces this risk without compromising control given the low A1c. Decreasing insulin glargine while continuing glipizide is suboptimal as it does not address the primary culprit, and switching to glyburide worsens hypoglycemia risk due to its longer duration. Increasing metformin or continuing glipizide ignores the hypoglycemia and may not adequately mitigate risks. A key clinical pearl is to prioritize de-escalation of high-hypoglycemia-risk agents like sulfonylureas when A1c is below 7% in older patients. Use a framework of assessing A1c, hypoglycemia frequency, and agent risk profiles to guide deprescribing in diabetes management.

Question 9

1. Continue amoxicillin and add diphenhydramine; hives are expected early in therapy
2. Stop amoxicillin, recommend contacting the prescriber for an alternative, and document a probable penicillin allergy (correct answer)
3. Switch amoxicillin to ampicillin 500 mg by mouth three times daily
4. Increase amoxicillin to 875 mg by mouth three times daily to overcome intolerance

Explanation: This question tests the management of probable penicillin allergy during antibiotic therapy. The key patient-specific factor is hives and itching after the second amoxicillin dose, suggesting an IgE-mediated reaction requiring avoidance. Stopping amoxicillin, contacting the prescriber for an alternative, and documenting the allergy is best to prevent escalation to anaphylaxis. Continuing with diphenhydramine, switching to ampicillin, or increasing dose risks severe reactions. A clinical pearl is that beta-lactam allergies should be clarified by reaction type, with immediate hypersensitivity warranting class avoidance. Use a framework of evaluating reaction timing and symptoms to guide discontinuation and allergy documentation for future prescribing.

Question 10

1. Continue metformin 1000 mg twice daily and add glyburide 5 mg by mouth daily
2. Discontinue metformin due to low eGFR and reassess glycemic regimen (correct answer)
3. Increase metformin to 1500 mg by mouth twice daily to improve A1c
4. Switch metformin to extended-release 2000 mg by mouth daily to improve renal safety

Explanation: This question tests the recognition of metformin contraindications in patients with impaired renal function. The key patient-specific factor is the eGFR of 26 mL/min/1.73 m², which is below the threshold for safe metformin use due to lactic acidosis risk. Discontinuing metformin and reassessing the glycemic regimen is the best choice as guidelines contraindicate metformin when eGFR is below 30 mL/min/1.73 m². Continuing or increasing metformin, adding glyburide, or switching to extended-release ignores the renal impairment and heightens adverse event risk. A clinical pearl is that metformin accumulation in CKD can lead to rare but serious lactic acidosis, necessitating prompt discontinuation. Apply a decision framework of routinely checking eGFR before and during metformin therapy, with discontinuation if below 30 mL/min/1.73 m² and alternative agents like SGLT2 inhibitors if appropriate.

Question 11

1. Recommend ibuprofen 400 mg by mouth three times daily as needed
2. Recommend naproxen 500 mg by mouth twice daily as needed
3. Recommend acetaminophen as needed and avoid routine nonsteroidal anti-inflammatory drugs due to bleeding risk (correct answer)
4. Recommend aspirin 325 mg by mouth daily for pain control

Explanation: This question tests safe analgesic selection in patients on anticoagulants with bleeding risk. The key patient-specific factor is apixaban use with low hemoglobin, making NSAIDs like ibuprofen or naproxen high-risk for gastrointestinal bleeding. Recommending acetaminophen and avoiding routine NSAIDs is best due to its lower bleeding risk profile in anticoagulated patients. Aspirin also increases bleeding, and all NSAIDs are contraindicated without strong need. A clinical pearl is that NSAIDs potentiate anticoagulant effects, especially in older adults with comorbidities. Employ a framework of assessing bleeding risk factors and prioritizing non-NSAID options like acetaminophen for pain management in such populations.

Question 12

1. Add lorazepam 1 mg by mouth nightly for improved sleep quality
2. Recommend deprescribing high-risk sedatives (e.g., diphenhydramine) and reassessing zolpidem dose due to fall risk (correct answer)
3. Increase zolpidem to 20 mg by mouth nightly to prevent nighttime awakenings
4. Switch diphenhydramine to hydroxyzine 50 mg by mouth nightly for safer sedation

Explanation: This question tests deprescribing in older adults with polypharmacy and fall risk. The key patient-specific factor is multiple sedatives (zolpidem, diphenhydramine, etc.) contributing to falls via CNS depression. Recommending deprescribing high-risk sedatives and reassessing zolpidem is best to minimize fall risk while addressing insomnia. Adding lorazepam, increasing zolpidem, or switching to hydroxyzine increases sedation burden. A clinical pearl is that Beers criteria highlight sedatives like non-benzodiazepine hypnotics and antihistamines as high-risk for falls in elderly. Use a framework of evaluating medication lists for CNS-active agents and prioritizing gradual deprescribing to enhance safety.

Question 13

1. Topiramate may reduce contraceptive effectiveness; use a backup method and discuss alternatives (correct answer)
2. Take the contraceptive only during weeks when migraines occur
3. Stop topiramate abruptly to avoid interaction with the contraceptive
4. Double the contraceptive dose if a pill is missed to maintain hormone levels

Explanation: This question tests counseling on drug interactions affecting hormonal contraceptive efficacy. The key patient-specific factor is topiramate use, which induces CYP3A4 and can reduce ethinyl estradiol levels, decreasing contraceptive effectiveness. Counseling on reduced efficacy, backup methods, and alternatives is most important to prevent unintended pregnancy. Taking only during migraines, stopping topiramate abruptly, or doubling doses is unsafe and ineffective. A clinical pearl is that enzyme inducers like topiramate (>200 mg/day) necessitate higher estrogen doses or non-hormonal contraception. Apply a framework of reviewing concomitant medications for induction potential and advising on barrier methods during and for 28 days after inducer use.

Question 14

1. Frequent blood glucose monitoring during steroid therapy and for several days after completion (correct answer)
2. INR monitoring every 48 hours
3. Serum digoxin concentration
4. Serum troponin daily

Explanation: This question tests monitoring for corticosteroid-induced hyperglycemia in diabetic patients. The key patient-specific factor is elevated glucose readings since starting prednisone, a known effect of systemic steroids in diabetes. Prioritizing frequent blood glucose monitoring during and after therapy is essential to detect and manage hyperglycemia promptly. INR, digoxin, or troponin are irrelevant without anticoagulation, digoxin use, or cardiac concerns. A clinical pearl is that steroids can cause dose-dependent hyperglycemia peaking 4-8 hours post-dose, necessitating intensified monitoring. Use a framework of anticipating metabolic effects and adjusting diabetes regimens based on glucose trends during short-term steroid courses.

Question 15

1. Continue colchicine and clarithromycin; counsel that diarrhea is expected and will resolve in 1–2 weeks
2. Increase colchicine to 1.2 mg twice daily to shorten flare duration
3. Hold colchicine and contact the prescriber due to a major interaction with clarithromycin that increases colchicine toxicity risk (correct answer)
4. Switch clarithromycin to azithromycin 1 g once daily for 3 days without prescriber involvement and continue colchicine

Explanation: This question tests recognition of a major drug interaction causing colchicine toxicity. Clarithromycin is a potent CYP3A4 and P-glycoprotein inhibitor that dramatically increases colchicine levels, causing severe gastrointestinal toxicity (diarrhea, cramping) and potentially life-threatening complications. The patient's reduced creatinine clearance (55 mL/min) further increases risk. Immediate discontinuation of colchicine and prescriber notification is essential. Continuing both drugs (choice A) risks serious toxicity including rhabdomyolysis and multi-organ failure. Increasing colchicine (choice B) would worsen toxicity. Independently switching antibiotics (choice D) exceeds pharmacist scope and may not adequately treat the pneumonia. When patients require colchicine for acute gout flares while on strong CYP3A4 inhibitors like clarithromycin, alternative gout treatments (NSAIDs, corticosteroids) should be used, or wait until antibiotic course completion.

Question 16

1. Continue all medications as listed because each contains low-dose acetaminophen
2. Discontinue standalone acetaminophen and ensure total daily acetaminophen from all sources does not exceed 3000–4000 mg (correct answer)
3. Switch oxycodone/acetaminophen to hydrocodone/acetaminophen 10/325 mg every 6 hours as needed to reduce liver risk
4. Increase acetaminophen to 1000 mg by mouth four times daily and stop oxycodone/acetaminophen

Explanation: This question tests the prevention of acetaminophen hepatotoxicity in patients using multiple acetaminophen-containing products. The key patient-specific factor is elevated liver enzymes in a patient taking oxycodone/acetaminophen plus standalone acetaminophen, risking overdose. Discontinuing standalone acetaminophen and limiting total daily intake to 3000-4000 mg is best to prevent hepatotoxicity while maintaining pain control. Continuing all, switching opioids, or increasing acetaminophen heightens liver risk without benefit. A clinical pearl is that unintentional acetaminophen overdose often occurs from combination products, especially in those with liver disease. Employ a framework of calculating total acetaminophen exposure from all sources and educating on maximum daily limits to ensure safe use.

Question 17

1. Continue timolol and add montelukast 10 mg by mouth nightly
2. Switch timolol ophthalmic to a nonselective oral beta-blocker for better glaucoma control
3. Recommend discussing alternative glaucoma therapy because timolol can worsen bronchospasm (correct answer)
4. Increase fluticasone/salmeterol to 500/50 mcg twice daily and continue timolol

Explanation: This question tests the management of systemic beta-blocker effects from ophthalmic formulations in patients with asthma. The key patient-specific factor is worsening wheezing after starting timolol eye drops, as nonselective beta-blockers can cause bronchospasm even topically due to systemic absorption. Recommending discussion of alternative glaucoma therapy is best because timolol's beta-blockade exacerbates asthma, and options like prostaglandin analogs may be safer. Continuing timolol with montelukast or increasing inhaled steroids does not eliminate the risk, while switching to oral beta-blockers worsens it. A clinical pearl is that ophthalmic beta-blockers can have pulmonary effects, particularly in asthma patients, necessitating alternatives. Use a framework of evaluating comorbid conditions and drug routes to identify and mitigate unintended systemic adverse effects.

Question 18

1. Continue lisinopril and add diphenhydramine 25 mg by mouth every 6 hours as needed
2. Stop lisinopril and recommend urgent evaluation due to possible angioedema (correct answer)
3. Switch lisinopril to enalapril 10 mg by mouth daily
4. Reduce lisinopril to 5 mg by mouth daily and monitor symptoms for 2 weeks

Explanation: This question tests the recognition and management of angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema. The key patient-specific factor is the new onset of dry cough and mild lip swelling shortly after starting lisinopril, suggestive of angioedema. Stopping lisinopril and recommending urgent evaluation is the best choice because ACEI-induced angioedema can progress to life-threatening airway compromise and requires immediate discontinuation. Continuing lisinopril with diphenhydramine or reducing the dose risks escalation of symptoms, while switching to another ACEI like enalapril is inappropriate due to class-wide risk. A clinical pearl is that ACEI angioedema often presents with facial or lip swelling and can occur at any time during therapy, though commonly early on. Employ a decision framework of assessing symptom timing relative to drug initiation and prioritizing discontinuation for suspected serious adverse reactions like angioedema.

Question 19

1. Recommend taking levothyroxine only on days when symptoms of fatigue occur
2. Counsel to take levothyroxine consistently on an empty stomach and separate from calcium/iron by at least 4 hours, and use a daily reminder system (correct answer)
3. Switch levothyroxine to liothyronine 25 mcg by mouth daily for faster symptom relief
4. Double the levothyroxine dose the next day whenever a dose is missed

Explanation: This question tests interventions for medication non-adherence in thyroid hormone replacement therapy. The key patient-specific factor is inconsistent levothyroxine use due to forgetting doses, compounded by concurrent calcium and iron intake that impairs absorption, leading to elevated TSH. Counseling on consistent empty-stomach administration, separating from calcium/iron by 4 hours, and using reminders is the best intervention to optimize absorption and adherence. Taking only when symptomatic, switching to liothyronine, or doubling missed doses risks under- or over-treatment and inconsistent levels. A clinical pearl is that levothyroxine requires fasting administration for maximal bioavailability, and adherence barriers like forgetfulness can be addressed with tools like pill organizers. Use a decision framework of evaluating TSH trends, absorption interferers, and patient routines to tailor adherence strategies in hypothyroidism management.

Question 20

1. Continue allopurinol and add topical hydrocortisone for the rash
2. Stop allopurinol and recommend urgent evaluation due to possible severe hypersensitivity reaction (correct answer)
3. Increase allopurinol to 600 mg by mouth daily to suppress inflammation
4. Switch allopurinol to febuxostat 80 mg by mouth daily immediately without evaluation

Explanation: This question tests the identification of allopurinol hypersensitivity syndrome. The key patient-specific factor is fever, widespread rash, and elevated liver enzymes shortly after starting allopurinol, indicative of a severe reaction like DRESS syndrome. Stopping allopurinol and recommending urgent evaluation is best as hypersensitivity can progress to multi-organ involvement requiring immediate cessation. Adding hydrocortisone, increasing dose, or switching to febuxostat without evaluation delays care and risks continuation of harm. A clinical pearl is that allopurinol hypersensitivity often occurs within weeks and is more common in those with renal impairment or on thiazides. Use a framework of correlating symptom onset with drug initiation and prioritizing discontinuation for suspected severe cutaneous reactions.